Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aggrescan4D, A comprehensive tool for pH-dependent analysis and engineering of protein aggregation propensity

  • Zalewski, Mateusz|||0000-0002-3436-8829
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Ventura, Salvador|||0000-0002-9652-6351
  • Kmiecik, Sebastian|||0000-0001-7623-0935
Aggrescan4D (A4D) is an advanced computational tool designed for predicting protein aggregation, leveraging structural information and the influence of pH. Building upon its predecessor, Aggrescan3D (A3D), A4D has undergone numerous enhancements aimed at assisting the improvement of protein solubility. This manuscript reviews A4D's updated functionalities and explains the fundamental principles behind its pH-dependent calculations. Additionally, it presents an antibody case study to evaluate its performance in comparison with other structure-based predictors. Notably, A4D integrates advanced protein engineering protocols with pH-dependent calculations, enhancing its utility in advising solubility-enhancing mutations. A4D considers the impact of structural flexibility on aggregation propensities, and includes a large set of precalculated predictions. These capabilities should help to open new avenues for both understanding and managing protein aggregation. A4D is accessible through a dedicated web server at https://biocomp.chem.uw.edu.pl/a4d/.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aggregating amyloid resources, A comprehensive review of databases on amyloid-like aggregation

  • Iglesias, Valentin|||0000-0002-6133-0869
  • Chilimoniuk, Jaroslaw|||0000-0001-5467-018X
  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Ventura, Salvador|||0000-0002-9652-6351
  • Burdukiewicz, Michał|||0000-0001-8926-582X
Protein aggregation is responsible for several degenerative conditions in humans, and it is also a bottleneck in industrial protein production and storage of biotherapeutics. Bioinformatics tools have been developed to predict and redesign protein solubility more efficiently by understanding the underlying principles behind aggregation. As more experimental data become available, dedicated resources for storing, indexing, classifying and consolidating experimental results have emerged. These resources vary in focus, including aggregation-prone regions, 3D patches or protein stretches capable of forming amyloid fibrils. Some of these resources also consider the experimental conditions that cause protein aggregation and how they affect the process. This review article explores how protein aggregation databases have evolved and surveys state-of-the-art resources. We highlight their applications, complementarity and existing limitations. Moreover, we showcase the existing symbiosis between amyloid-related databases and predictive tools. To increase the usefulness of our review, we supplement it with a comprehensive list of present and past amyloid databases: https://biogenies.info/amyloid-database-list/.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The role of amphipathic and cationic helical peptides in Parkinson's disease

  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Ventura, Salvador|||0000-0002-9652-6351
Peptides are attracting a growing interest for therapeutic applications in biomedicine. In Parkinson's disease (PD), different human endogenous peptides have been associated with beneficial effects, including protein aggregation inhibition, reduced inflammation, or the protection of dopaminergic neurons. Such effects seem to be connected to the spatial arrangement of peptide side chains, and many of these human molecules share common conformational traits, displaying a distinctive amphipathic and cationic helical structure, which is believed to be crucial for their activities. This review delves into the relationship between these structural properties and the current evidence connecting biogenic peptides to the amelioration of PD symptoms. We discuss their implications in the disease, the different mechanisms of action, their state of validation, and their therapeutic potential.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The small molecule -2 inhibits the aggregation and seeded polymerisation of C-terminally truncated α-Synuclein

  • Peña Díaz, Samuel|||0000-0002-2902-823X
  • Ventura, Salvador|||0000-0002-9652-6351
Protein aggregation, particularly the formation of amyloid fibrils, is associated with numerous human disorders, including Parkinson's disease. This neurodegenerative condition is characterised by the accumulation of α-Synuclein amyloid fibrils within intraneuronal deposits known as Lewy bodies or neurites. C-terminally truncated forms of α-Synuclein are frequently observed in these inclusions in the brains of patients, and their increased aggregation propensity suggests a role in the disease's pathogenesis. This study demonstrates that the small molecule ZPD-2 acts as a potent inhibitor of both the spontaneous and seeded amyloid polimerisation of C-terminally truncated α-Synuclein by interfering with early aggregation intermediates. This dual activity positions this molecule as a promising candidate for therapeutic development in treating synucleinopathies. The aggregation of α-Synuclein plays a key role in Parkinson's disease. Remarkably, the C-terminal region of this protein contributes to inhibit amyloid formation and its truncation enhances this process. In this work, we demonstrated that the addition of small molecules, ZPD-2 or SynuClean-D, inhibits the aggregation of C-terminally truncated α-Synuclein. Overall, the data suggested different inhibitory mechanisms with ZPD-2 outperforming SC-D by acting at the initial stages of aggregation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy

  • Camarero-Hoyos, Claudia
  • Bouzón-Arnáiz, Inés
  • Avalos-Padilla, Yunuen|||0000-0003-4074-5624
  • Fallica, Antonino Nicolò|||0000-0003-1899-8414
  • Román-Álamo, Lucía
  • Ramírez Moreno, Miriam|||0000-0002-9823-319X
  • Portabella, Emma
  • Cuspinera, Ona
  • Currea-Ayala, Daniela
  • Orozco-Quer, Marc
  • Ribera, Maria
  • Siden-Kiamos, Inga|||0000-0003-1572-5840
  • Spanos, Lefteris
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Crespo, Benigno
  • Viera, Sara|||0000-0002-2025-4804
  • Andreu Martínez, David|||0000-0002-6317-6666
  • Sulleiro, Elena|||0000-0002-9783-6060
  • Zarzuela, Francesc
  • Urtasun, Nerea|||0000-0003-1093-2269
  • Pérez-Torras, Sandra|||0000-0002-2785-5602
  • Pastor-Anglada, Marçal|||0000-0003-3712-1773
  • Arce, Elsa M.|||0000-0003-3757-5468
  • Muñoz-Torrero López-Ibarra, Diego|||0000-0002-8140-8555
  • Fernández Busquets, Xavier|||0000-0002-4622-9631
Background/Objectives : YAT2150 is a first-in-class antiplasmodial compound that has been recently proposed as a new interesting drug for malaria therapy. Methods/Results : The fluorescence of YAT2150 rapidly increases upon its entry into Plasmodium, a property that can be of use for the design of highly sensitive diagnostic approaches. YAT2150 blocks the in vitro development of the ookinete stage of Plasmodium and, when added to an infected blood meal, inhibits oocyst formation in the mosquito. Thus, the compound could possibly contribute to future transmission-blocking antimalarial strategies. Cell influx/efflux studies in Caco-2 cells suggest that YAT2150 is internalized by endocytosis and also through the OATP2B1 transporter, whereas its main export route would be via OSTα. YAT2150 has an overall favorable drug metabolism and pharmacokinetics profile, and its moderate cytotoxicity can be significantly reduced upon encapsulation in immunoliposomes, which leads to a dramatic increase in the drug selectivity index to values close to 1000. Although YAT2150 binds amyloid-forming peptides, its in vitro fluorescence emission is stronger upon association with peptides that form amorphous aggregates, suggesting that regions enriched in unstructured proteins are the preferential binding sites of the drug inside Plasmodium cells. The reduction of protein aggregation in the parasite after YAT2150 treatment, which has been suggested to be directly related to the drug's mode of action, is also observed following treatment with quinoline antimalarials like chloroquine and primaquine. Conclusions : Altogether, the data presented here indicate that YAT2150 can represent the spearhead of a new family of compounds for malaria diagnosis and therapy due to its presumed novel mode of action based on the interaction with functional protein aggregates in the pathogen.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Determinants of alpha-synuclein pathogenesis in Parkinson's disease

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Structural information in therapeutic peptides, Emerging applications in biomedicine

  • Iglesias, Valentin|||0000-0002-6133-0869
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Burdukiewicz, Michał|||0000-0001-8926-582X
  • Ventura, Salvador|||0000-0002-9652-6351
Peptides are attracting a growing interest as therapeutic agents. This trend stems from their cost-effectiveness and reduced immunogenicity, compared to antibodies or recombinant proteins, but also from their ability to dock and interfere with large protein-protein interaction surfaces, and their higher specificity and better biocompatibility relative to organic molecules. Many tools have been developed to understand, predict, and engineer peptide function. However, most state-of-the-art approaches treat peptides only as linear entities and disregard their structural arrangement. Yet, structural details are critical for peptide properties such as solubility, stability, or binding affinities. Recent advances in peptide structure prediction have successfully addressed the scarcity of confidently determined peptide structures. This review will explore different therapeutic and biotechnological applications of peptides and their assemblies, emphasizing the importance of integrating structural information to advance these endeavors effectively.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mass spectrometry footprinting reveals how kinetic stabilizers counteract transthyretin dynamics altered by pathogenic mutations

  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Kant, Ravi|||0000-0002-0099-4346
  • Chemuru, Saketh
  • Varejão, Nathalia|||0000-0002-6952-8896
  • Velázquez-Campoy, Adrián|||0000-0001-5702-4538
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Gross, Michael L.|||0000-0003-1159-4636
  • Ventura, Salvador|||0000-0002-9652-6351
The aggregation of transthyretin (TTR) results in life-threatening transthyretin amyloidosis. Familial forms of the disease arise from point mutations that destabilize the TTR tetramer, leading to its dissociation and/or monomer unfolding and subsequent formation of amyloid fibrils. Small molecules that kinetically stabilize the native tetramer effectively inhibit this aggregation. Although over 300 X-ray crystal structures of TTR have been determined, these data refer to a static structure and do not capture the conformational effects of mutations and ligand binding. Here, we demonstrate that hydrogen-deuterium exchange (HDX) and fast photochemical oxidation of proteins (FPOP) coupled with mass spectrometry (MS) offer critical insights into the conformational dynamics associated with TTR amyloidogenic mutations and the binding of kinetic stabilizers. The results indicate that the design of TTR binders should consider the specific conformational traits of each TTR pathogenic variant. We propose that incorporating MS-based techniques into TTR drug discovery will expedite the development of effective pathology-specific aggregation inhibitors.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

AGGRESCAN and its evolution, A two-decade perspective on protein aggregation prediction

  • Pesce, Giulia|||0000-0002-3979-6072
  • Solé Pozas, Josep Oriol|||0009-0008-0005-6174
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Ventura, Salvador|||0000-0002-9652-6351
Protein aggregation is a widespread phenomenon with profound biological, biomedical, and biotechnological implications. In human disease, aberrant protein self-assembly is a hallmark of numerous neurodegenerative disorders, whereas in the biopharmaceutical industry, aggregation complicates the production, stability, and formulation of therapeutic proteins. The Aggrescan platform was one of the first empirically based tools designed to predict aggregation-prone regions (APRs) within protein sequences. It has since expanded to incorporate three-dimensional structural contexts and environmental conditions. This review provides a comprehensive overview of the development, application, and impact of the Aggrescan family of tools, which includes AGGRESCAN, Aggrescan3D, and the recent Aggrescan4D. We examine the algorithmic foundations, empirical validation, and key use cases spanning fields from biotechnology to biomedical research. Additionally, we describe how the recent integration of AlphaFold models has enabled proteome-scale exploration of aggregation determinants. This review highlights how Aggrescan has evolved alongside with advances in the field, becoming a reliable and accessible tool for studying and redesigning protein aggregation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comprehensive protein datasets and benchmarking for liquid-liquid phase separation studies

  • Pintado-Grima, Carlos|||0000-0002-8544-959X
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Arribas-Ruiz, Eva
  • Iglesias, Valentin|||0000-0002-6133-0869
  • Burdukiewicz, Michał|||0000-0001-8926-582X
  • Ventura, Salvador|||0000-0002-9652-6351
Proteins self-organize in dynamic cellular environments by assembling into reversible biomolecular condensates through liquid-liquid phase separation (LLPS). These condensates can comprise single or multiple proteins, with different roles in the ensemble's structural and functional integrity. Driver proteins form condensates autonomously, while client proteins just localize within them. Although several databases exist to catalog proteins undergoing LLPS, they often contain divergent data that impedes interoperability between these resources. Additionally, there is a lack of consensus on selecting proteins without explicit experimental association with condensates under physiological conditions (non-LLPS proteins or negative proteins). These two aspects have prevented the generation of reliable predictive models and fair benchmarks. In this work, we use an integrated biocuration protocol to analyze information from all relevant LLPS databases and generate confident datasets of client and driver proteins. We introduce standardized negative datasets, encompassing both globular and disordered proteins. To validate our datasets, we investigate specific physicochemical traits related to LLPS across different subsets of protein sequences and benchmark them against 16 predictive algorithms. We observe significant differences not only between positive and negative instances but also among LLPS proteins themselves. The datasets from this study are available as a website at and as a data repository at . Our datasets offer a reliable means for confidently assessing the specific roles of proteins in LLPS and identifying key differences in physicochemical properties underlying this process. Moreover, we describe limitations in classical and state-of-the-art predictive algorithms by providing the most comprehensive benchmark to date. {'@id': 'Par4', 'graphic': {'@position': 'anchor', '@id': 'MO1', '@orientation': 'portrait', '@xlink:href': '13059_2025_3668_Figa_HTML.jpg'}} The online version contains supplementary material available at 10.1186/s13059-025-03668-6.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mass spectrometry footprinting reveals how kinetic stabilizers counteract transthyretin dynamics altered by pathogenic mutations

  • Pinheiro, Francisca
  • Kant, Ravi
  • Chemuru, Saketh
  • Varejão, Nathalia
  • Velázquez-Campoy, Adrián
  • Reverter, David
  • Pallarès, Irantzu
  • Gross, Michael L.
  • Ventura, Salvador
The aggregation of transthyretin (TTR) results in life-threatening transthyretin amyloidosis. Familial forms of the disease arise from point mutations that destabilize the TTR tetramer, leading to its dissociation and/or monomer unfolding and subsequent formation of amyloid fibrils. Small molecules that kinetically stabilize the native tetramer effectively inhibit this aggregation. Although over 300 X-ray crystal structures of TTR have been determined, these data refer to a static structure and do not capture the conformational effects of mutations and ligand binding. Here, we demonstrate that hydrogen–deuterium exchange (HDX) and fast photochemical oxidation of proteins (FPOP) coupled with mass spectrometry (MS) offer critical insights into the conformational dynamics associated with TTR amyloidogenic mutations and the binding of kinetic stabilizers. The results indicate that the design of TTR binders should consider the specific conformational traits of each TTR pathogenic variant. We propose that incorporating MS-based techniques into TTR drug discovery will expedite the development of effective pathology-specific aggregation inhibitors.